Early Treatment of Acute Graft Versus Host Disease With Bone Marrow-Derived Mesenchymal Stem Cells and Corticosteroids
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02379442
Recruitment Status :
First Posted : March 5, 2015
Results First Posted : May 1, 2019
Last Update Posted : May 1, 2019
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Heart, Lung, and Blood Institute (NHLBI) )
One subject completed the protocol, and the FDA placed the study on hold due to NIH operational issues. Since the cellular product of bone-marrow derived mesenchymal stem cells is no longer available, the protocol was terminated on December 13, 2017.